PPLPHARMA - Technical Analysis with Chart Patterns & Indicators
← Back to ListKey Parameters
⭐ Technical Rating: 3.8
✅ Positive
The stock exhibits strong recent revenue growth, reported at 17% in Q1FY26, coupled with a positive expert outlook suggesting a potential target price of Rs 238. Additionally, the company maintains a relatively low debt-to-equity ratio and a favorable PEG ratio.
⚠️ Limitation
The significant decline in FII holding (-17.7%) raises concerns about institutional investor confidence. Furthermore, the dramatic drop in PAT from Qtr 3 (Rs 313 Cr.) to Qtr 4 (Rs 113 Cr.) presents a notable negative trend that warrants caution.
📉 Company Negative News
Recent news indicates an "expert sees Rs 238 target after breakout" with an optimistic outlook, however, another article suggests selling on the rally due to recent profit declines and a potential for further decline towards its all-time high.
📈 Company Positive News
The news highlights a 17% revenue growth in Q1FY26, fueling optimism surrounding the company's performance within the pharmaceutical sector.
🏭 Industry
The pharmaceutical industry is currently experiencing moderate growth driven by increasing demand for generic drugs and contract manufacturing services. However, competitive pressures and regulatory changes remain key challenges, influencing valuations across companies like Piramal Pharma.
🧾 Conclusion
Based on the current price of 196 ₹, a potential entry zone could be established between 192-195 ₹, utilizing support levels derived from recent lows. An exit strategy should be implemented around resistance at 203 ₹, or if the RSI moves below 60. Overall, while showing growth, volatility and decreased institutional holdings suggest a cautiously optimistic outlook with moderate upside potential.